RSLS Stock Overview Provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ReShape Lifesciences Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ReShape Lifesciences Historical stock prices Current Share Price US$4.38 52 Week High US$29.00 52 Week Low US$4.09 Beta 1.38 1 Month Change -21.08% 3 Month Change -45.18% 1 Year Change -74.62% 3 Year Change -99.92% 5 Year Change -99.97% Change since IPO -100.00%
Recent News & Updates
ReShape Lifesciences Receives Written Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5550(b)(1) Dec 03
Third quarter 2024 earnings released: US$3.12 loss per share (vs US$59.37 loss in 3Q 2023) Nov 17
ReShape Lifesciences Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 13 ReShape Lifesciences Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX ReShape Lifesciences Inc. announced that it expects to receive $0.833333 million in funding Oct 18
Second quarter 2024 earnings released: US$0.063 loss per share (vs US$1.08 loss in 2Q 2023) Aug 16 See more updates
ReShape Lifesciences Receives Written Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5550(b)(1) Dec 03
Third quarter 2024 earnings released: US$3.12 loss per share (vs US$59.37 loss in 3Q 2023) Nov 17
ReShape Lifesciences Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 13 ReShape Lifesciences Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX ReShape Lifesciences Inc. announced that it expects to receive $0.833333 million in funding Oct 18
Second quarter 2024 earnings released: US$0.063 loss per share (vs US$1.08 loss in 2Q 2023) Aug 16
ReShape Lifesciences Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 13
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 17
ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024 May 16
The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement Apr 11
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 02
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System Mar 29
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex Feb 22
ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024 Jan 25
Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded Nov 28
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 10
ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 07
ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq Oct 16 ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device Sep 15
Consensus revenue estimates decrease by 23%, EPS upgraded Aug 14
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 08
ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023 Aug 04
ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting Jun 29
ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0 Jun 27
Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded May 22
ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023 May 12
Consensus EPS estimates upgraded to US$16.50 loss Apr 25
Full year 2022 earnings: EPS misses analyst expectations Apr 18
It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS) Apr 18 ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million. Feb 08
ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million. Feb 07
Consensus revenue estimates fall by 16% Nov 21
ReShape Lifesciences Inc. Provides Revenue Guidance Nov 16
Price target decreased to US$1.03 Nov 16
Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021) Nov 16
ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022 Nov 11
ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 08
Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band® Nov 01
ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery Oct 21
Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations Aug 24
ReShape Lifesciences Inc. announced delayed 10-Q filing Aug 17
Price target decreased to US$3.08 Aug 13
Insufficient new directors Aug 13 Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures
ReShape wins FDA clearance for device used in weight loss surgery Aug 10 ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022
ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq Jul 26
ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022 May 17
ReShape Lifesciences Inc. announced delayed 10-Q filing May 14 ReShape Lifesciences Inc. announced delayed annual 10-K filing Apr 03
Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results Mar 31
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 30
Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt? Dec 09
Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020) Nov 13
Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet? Aug 24
Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020) Aug 18
High number of new directors Jul 31
Consensus forecasts updated Jul 02
Consensus forecasts updated Jun 18
Price target decreased to US$12.00 Jun 17
ReShape Lifesciences Inc. (OTCPK:RSLS) completed the acquisition of Obalon Therapeutics, Inc. (NasdaqCM:OBLN) in a reverse merger transaction. Jun 16
ReShape Lifesciences Inc. (OTCPK:RSLS) entered into an agreement to acquire Obalon Therapeutics, Inc. (NasdaqCM:OBLN). Jan 22
ReShape Lifesciences Inc. to Report Q2, 2020 Results on Aug 13, 2020 Aug 12 Shareholder Returns RSLS US Medical Equipment US Market 7D -7.2% -1.5% -2.4% 1Y -74.6% 10.0% 23.4%
See full shareholder returns
Return vs Market: RSLS underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is RSLS's price volatile compared to industry and market? RSLS volatility RSLS Average Weekly Movement 14.3% Medical Equipment Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: RSLS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RSLS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual’s comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus.
Show more ReShape Lifesciences Inc. Fundamentals Summary How do ReShape Lifesciences's earnings and revenue compare to its market cap? RSLS fundamental statistics Market cap US$3.12m Earnings (TTM ) -US$7.07m Revenue (TTM ) US$8.18m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RSLS income statement (TTM ) Revenue US$8.18m Cost of Revenue US$2.60m Gross Profit US$5.58m Other Expenses US$12.65m Earnings -US$7.07m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -9.92 Gross Margin 68.19% Net Profit Margin -86.36% Debt/Equity Ratio 0%
How did RSLS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 07:21 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ReShape Lifesciences Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution William Plovanic Canaccord Genuity Matthew Hewitt Craig-Hallum Capital Group LLC Jeffrey Cohen Ladenburg Thalmann & Company
Show 5 more analysts 
